Condition (MeSH)
Epidermolysis Bullosa, Junctional
ClinicalTrials.gov lists 16 trials for Epidermolysis Bullosa, Junctional or a narrower condition beneath it. Chiesi Farmaceutici S.p.A. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Epidermolysis Bullosa, Junctional itself; the rest are tagged with a narrower condition beneath it.
When did Epidermolysis Bullosa, Junctional trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 3 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 1 |
| 2007 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 23 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 5 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Epidermolysis Bullosa, Junctional trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 4 |
How many Epidermolysis Bullosa, Junctional trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Completed | 2 |
| Terminated | 3 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Epidermolysis Bullosa, Junctional trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Chiesi Farmaceutici S.p.A. | 2 |
| Castle Creek Pharmaceuticals, LLC | 1 |
| Energenesis Biomedical Co., Ltd. | 1 |
| Holostem s.r.l. | 1 |
| InMed Pharmaceuticals Inc. | 1 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Epidermolysis Bullosa, Junctional? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RGN-137 | 1 |
| Filsuvez | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Oleogel-S10 | 1 |
| ENERGI-F703EB Cream | 1 |
| Vehicle Cream | 1 |
| Gentamicins | 1 |
| INM-755 (cannabinol) cream | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Epidermolysis Bullosa, Junctional? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants. | JAMA dermatology | 2022 | Yes |
| Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. | Pediatric dermatology | 2015 | No |
Prevalence (39)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Junctional epidermolysis bullosa | Point prevalence | <1 / 1 000 000 | United States | US | Exact |
| Junctional epidermolysis bullosa | Prevalence at birth | 1-9 / 1 000 000 | United States | US | Unspecified |
| Junctional epidermolysis bullosa | Prevalence at birth | 1-9 / 1 000 000 | United States | US | Exact |
| Junctional epidermolysis bullosa | Point prevalence | <1 / 1 000 000 | United States | US | Exact |
| Junctional epidermolysis bullosa | Prevalence at birth | 1-9 / 1 000 000 | United States | US | Exact |
Showing 5 of 39 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Junctional epidermolysis bullosa | 305 | Exact | Orphadata Science knowledge files, Product 1 |
| Junctional epidermolysis bullosa | 305 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.